Predictive biomarkers for MGMT-promoter-methylated glioblastoma (A05)

MGMT 启动子甲基化胶质母细胞瘤的预测生物标志物 (A05)

• 批准号: 424447858
• 金额: --
• 依托单位: Abteilung Neuropathologie
• 依托单位国家: 德国
• 项目类别: Collaborative Research Centres
• 财政年份: 2019
• 资助国家: 德国
• 起止时间: 2018-12-31 至 2022-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/424447858?language=en
• 关键词: Predictive; biomarkers; MGMT; promoter; methylated

By analysis of the mutational spectrum, DNA methylation patterns, chromosomal aberrations, and proteome profiles of tumor tissues from glioblastoma patients with O6-methylguanine DNA-methyltransferase (MGMT) promoter methylation and response (>15 months progression-free-survival) vs. patients with no response (<6 months) to combined radiochemotherapy with temozolomide, we aim to identify novel predictive tissue-biomarkers for temozolomide response and resistance in glioblastoma patients. These novel predictive markers are expected to have a direct impact on clinical decision making with improved predictive power when compared to MGMT methylation status alone.

通过分析O6-甲基鸟嘌呤DNA-甲基转移酶(MGMT)启动子甲基化和应答(15个月无进展无进展生存期)与放化疗联合替莫唑胺无应答(&lt；6个月)的胶质母细胞瘤患者肿瘤组织的突变谱、DNA甲基化模式、染色体畸变率和蛋白质组特征，我们旨在寻找新的预测替莫唑胺应答和耐药的组织生物标志物。与单独的MGMT甲基化状态相比，这些新的预测标记有望对临床决策产生直接影响，具有更好的预测能力。